Last reviewed · How we verify
armodafinil 150 mg
At a glance
| Generic name | armodafinil 150 mg |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder (PHASE4)
- Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma (PHASE3)
- Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer (PHASE1, PHASE2)
- Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury (PHASE3)
- Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury (PHASE3)
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy (PHASE1)
- Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies (NA)
- A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |